Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
IRWD moved a median of +0.07% 30 minutes after news, and -0.69% by the close. How IRWD actually reacts to news — the realized, point-in-time move the market made, measured across 342 labeled events over the last three years with zero look-ahead.
IRWD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.05% | 48% | 341 |
| 30-min | +0.07% | 50% | 341 |
| 60-min | -0.12% | 47% | 341 |
| to close | -0.69% | 44% | 340 |
| Middle 50% of IRWD reactions | -1.25% to +1.50% |
|---|---|
| Median reaction (30-min) | +0.07% |
| Measured reactions | 342 |
Half of all Ironwood Pharmaceuticals, Inc. - Class A news events land between -1.25% and +1.50% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IRWD reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 21 | +0.73% | 62% | +1.10% |
| Analyst downgrades | 22 | -0.34% | 36% | -0.31% |
| Coverage initiations | 14 | +1.04% | 64% | +0.21% |
| Rating reiterations | 17 | 0.00% | 47% | 0.00% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how IRWD ranks against every other measured name →
That’s how IRWD usually reacts — get an email when it moves on news →Email me when IRWD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IRWD's baseline. Nothing else.
Recent IRWD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K IRONWOOD PHARMACEUTICALS For: Oct 12 | SEC filing · Form 8-K | SEC EDGAR | -3.48% | -6.17% | |
| Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer | Press release | Business Wire | -3.48% | -6.17% | |
| Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference | Press release | Business Wire | +1.06% | +0.71% | |
| Form 10-Q IRONWOOD PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.31% | +0.00% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +4.33% | +2.40% | |
| Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results | Press release | Business Wire | +4.33% | +2.40% | |
| Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call | Press release | Business Wire | -0.25% | +7.63% | |
| Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients | Press release | Business Wire | -1.43% | -4.79% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +1.53% | +6.11% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | -0.83% | -2.40% | |
| Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference | Press release | Business Wire | -1.10% | -1.65% | |
| FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC) | Press release | Business Wire | +0.69% | -5.24% | |
| Form 8-K/A IRONWOOD PHARMACEUTICALS For: May 08 | SEC filing · Form 8-K | SEC EDGAR | +0.78% | +1.55% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: May 08 | SEC filing · Form 8-K | SEC EDGAR | -2.00% | -8.00% | |
| Form 10-Q IRONWOOD PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -0.94% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -0.37% | -10.90% | |
| Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance | Press release | Business Wire | -0.37% | -10.90% | |
| Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS) | Press release | Business Wire | +0.23% | +5.52% | |
| Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call | Press release | Business Wire | +0.12% | +7.25% | |
| Form ARS IRONWOOD PHARMACEUTICALS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +3.80% | -1.43% | |
| Form DEF 14A IRONWOOD PHARMACEUTICALS For: Jun 16 | SEC filing · Form DEF | SEC EDGAR | +3.80% | -1.43% | |
| Form DEFA14A IRONWOOD PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | +3.80% | -1.43% | |
| Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026 | Press release | Business Wire | -0.48% | -8.89% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +1.63% | -0.27% | |
| Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference | Press release | Business Wire | +0.68% | -1.63% | |
| Form 10-K IRONWOOD PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.10% | -3.66% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | -15.37% | -6.92% | |
| Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook | Press release | Business Wire | -15.37% | -6.92% | |
| Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call | Press release | Business Wire | -2.95% | -2.95% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: Jan 02 | SEC filing · Form 8-K | SEC EDGAR | +6.75% | -6.97% | |
| Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance | Press release | Business Wire | +6.75% | -6.97% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | -2.46% | -1.23% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: Nov 25 | SEC filing · Form 8-K | SEC EDGAR | +1.50% | +15.92% | |
| Form 10-Q IRONWOOD PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +7.33% | +3.69% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +7.33% | +3.69% | |
| Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance | Press release | Business Wire | +7.33% | +3.69% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | -2.14% | -14.79% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: Aug 29 | SEC filing · Form 8-K | SEC EDGAR | -0.86% | -5.17% | |
| Form 10-Q IRONWOOD PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.61% | — | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +5.98% | -4.35% | |
| Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance | Press release | Business Wire | +5.98% | -4.35% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: Jul 03 | SEC filing · Form 8-K | SEC EDGAR | -0.53% | -3.56% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +0.84% | -3.55% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: May 28 | SEC filing · Form 8-K | SEC EDGAR | +2.07% | +0.69% | |
| Form 10-Q IRONWOOD PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.91% | -8.01% | |
| Form 8-K IRONWOOD PHARMACEUTICALS For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -5.34% | -15.80% | |
| Ironwood Pharmaceuticals Reports First Quarter 2025 Results | Press release | Business Wire | -5.34% | -15.80% | |
| Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference | Press release | Business Wire | -6.30% | -4.01% | |
| Form ARS IRONWOOD PHARMACEUTICALS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.05% | -3.12% | |
| Form DEF 14A IRONWOOD PHARMACEUTICALS For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | -0.05% | -3.12% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IRWD section they belong to.
Where else IRWD is measured.
IRWD earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| REGENERX BIOPHARMS INC (RGRX) | 343 | 0.00% | 36% |
| Allena Pharmaceuticals, Inc. (ALNA) | 342 | 0.00% | 41% |
| Brookdale Senior Living Inc. (BKD) | 341 | +0.36% | 62% |
| Vaxart, Inc. (VXRT) | 341 | -0.81% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Ironwood Pharmaceuticals, Inc. - Class A's median reaction calculated?
Every labeled IRWD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 342 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of IRWD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IRWD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.